A simple and reliable approach for assessing anticancer activity in vitro

Current Medicinal Chemistry

Volumn 22, Issue 11, 2015, Pages 1324-1334

  López Lázaro, Miguel ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Antitumor activity; Cancer; Cytotoxic activity; Drug discovery; Screening; Selectivity

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER PATIENT; CANCER THERAPY; CELL VIABILITY; CYTOTOXICITY; DRUG SCREENING; GENE EXPRESSION; HUMAN; IN VITRO STUDY; NONHUMAN; PATIENT CARE; RELIABILITY; REVIEW; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; NEOPLASMS; PATHOLOGY; PROCEDURES; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS;

EID: 84924943935     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150209150639     Document Type: Review

References (67)

1. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin., 2014, 64, 9-29.
2. Cheng, W.H.; Cao, B.; Shang, H.; Niu, C.; Zhang, L.M.; Zhang, Z.H.; Tian, D.L.; Zhang, S.; Chen, H.; Zou, Z.M. Synthesis and evaluation of novel podophyllotoxin derivatives as potential antitumor agents. Eur. J. Med. Chem., 2014, 85, 498-507.
3. Kim, J.H.; Yu, J.; Alexander, V.; Choi, J.H.; Song, J.; Lee, H.W.; Kim, H.O.; Choi, J.; Lee, S.K.; Jeong, L.S. Structure-activity relationships of 2′-modified-4′-selenoarabinofuranosyl-pyrimidines as anticancer agents. Eur. J. Med. Chem., 2014, 83, 208-225.
4. Alanazi, A.M.; Abdel-Aziz, A.A.; Al Suwaidan, I.A.; Abdel-Hamide, S.G.; Shawer, T.Z.; El Azab, A.S. Design, synthesis and biological evaluation of some novel substituted quinazolines as antitumor agents. Eur. J. Med. Chem., 2014, 79, 446-454.
5. Rodrigues, F.A.; Bomfim, I.S.; Cavalcanti, B.C.; Pessoa, C.O.; Wardell, J.L.; Wardell, S.M.; Pinheiro, A.C.; Kaiser, C.R.; Nogueira, T.C.; Low, J.N.; Gomes, L.R.; de Souza, M.V. Design, synthesis and biological evaluation of (E)-2-(2-arylhydrazinyl)quinoxalines, a promising and potent new class of anticancer agents. Bioorg. Med. Chem. Lett., 2014, 24, 934-939.
6. Liu, W.; Gust, R. Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. Chem. Soc. Rev., 2013, 42, 755-773.
7. Liu, Z.; Romero-Canelon, I.; Qamar, B.; Hearn, J.M.; Habtemariam, A.; Barry, N.P.; Pizarro, A.M.; Clarkson, G.J.; Sadler, P.J. The Potent Oxidant Anticancer Activity of Organoiridium Catalysts. Angew. Chem. Int. Ed Engl., 2014, 53, 3941-3946.
8. Shchekotikhin, A.E.; Glazunova, V.A.; Dezhenkova, L.G.; Luzikov, Y.N.; Buyanov, V.N.; Treshalina, H.M.; Lesnaya, N.A.; Romanenko, V.I.; Kaluzhny, D.N.; Balzarini, J.; Agama, K.; Pommier, Y.; Shtil, A.A.; Preobrazhenskaya, M.N. Synthesis and evaluation of new antitumor 3-aminomethyl-4,11-dihydroxynaphtho[2,3-f]indole-5,10-diones. Eur. J. Med. Chem., 2014, 86, 797-805.
9. Chen, W.; Shen, Y.; Li, Z.; Zhang, M.; Lu, C.; Shen, Y. Design and synthesis of 2-phenylnaphthalenoids as inhibitors of DNA topoisomeraseIIalpha and antitumor agents. Eur. J. Med. Chem., 2014, 86, 782-796.
10. Karki, R.; Park, C.; Jun, K.Y.; Jee, J.G.; Lee, J.H.; Thapa, P.; Kadayat, T.M.; Kwon, Y.; Lee, E.S. Synthesis, antitumor activity, and structure-activity relationship study of trihydroxylated 2,4,6-triphenyl pyridines as potent and selective topoisomerase II inhibitors. Eur. J. Med. Chem., 2014, 84, 555-565.
11. Wang, M.J.; Liu, Y.Q.; Chang, L.C.; Wang, C.Y.; Zhao, Y.L.; Zhao, X.B.; Qian, K.; Nan, X.; Yang, L.; Yang, X.M.; Hung, H.Y.; Yang, J.S.; Kuo, D.H.; Goto, M.; Morris-Natschke, S.L.; Pan, S.L.; Teng, C.M.; Kuo, S.C.; Wu, T.S.; Wu, Y.C.; Lee, K.H. Design, synthesis, mechanisms of action, and toxicity of novel 20(s)-sulfonylamidine derivatives of camptothecin as potent antitumor agents. J. Med. Chem., 2014, 57, 6008-6018.
12. Hayashi, Y.; Takeno, H.; Chinen, T.; Muguruma, K.; Okuyama, K.; Taguchi, A.; Takayama, K.; Yakushiji, F.; Miura, M.; Usui, T.; Hayashi, Y. Development of a new benzophenone-diketopiperazine-type potent antimicrotubule agent possessing a 2- pyridine structure. ACS Med. Chem. Lett., 2014, 5, 1094-1098.
13. Guan, Q.; Han, C.; Zuo, D.; Zhai, M.; Li, Z.; Zhang, Q.; Zhai, Y.; Jiang, X.; Bao, K.; Wu, Y.; Zhang, W. Synthesis and evaluation of benzimidazole carbamates bearing indole moieties for antiproliferative and antitubulin activities. Eur. J. Med. Chem., 2014, 87C, 306-315.
14. Yang, Z.; Wu, W.; Wang, J.; Liu, L.; Li, L.; Yang, J.; Wang, G.; Cao, D.; Zhang, R.; Tang, M.; Wen, J.; Zhu, J.; Xiang, W.; Wang, F.; Ma, L.; Xiang, M.; You, J.; Chen, L. Synthesis and biological evaluation of novel millepachine derivatives as a new class of tubulin polymerization inhibitors. J. Med. Chem., 2014, 57, 7977-7989.
15. Kamal, A.; Srinivasa, R.T.; Polepalli, S.; Shalini, N.; Reddy, V.G.; Subba Rao, A.V.; Jain, N.; Shankaraiah, N. Synthesis and biological evaluation of podophyllotoxin congeners as tubulin polymerization inhibitors. Bioorg. Med. Chem., 2014, 22, 5466-5475.
16. Zhu, C.; Zuo, Y.; Wang, R.; Liang, B.; Yue, X.; Wen, G.; Shang, N.; Huang, L.; Chen, Y.; Du, J.; Bu, X. Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence. J. Med. Chem., 2014, 57, 6364-6382.
17. Moreau, P.; Dezhenkova, L.G.; Anizon, F.; Nauton, L.; Thery, V.; Liang, S.; Kaluzhny, D.N.; Shtil, A.A. New Potent and Selective Inhibitor of Pim-1/3 Protein Kinases Sensitizes Human Colon Carcinoma Cells to Doxorubicin. Anticancer Agents Med. Chem., 2014, 14, 1228-1236.
18. Sangani, C.B.; Makawana, J.A.; Duan, Y.T.; Yin, Y.; Teraiya, S.B.; Thumar, N.J.; Zhu, H.L. Design, synthesis and molecular modeling of biquinoline-pyridine hybrids as a new class of potential EGFR and HER-2 kinase inhibitors. Bioorg. Med. Chem. Lett., 2014, 24, 4472-4476.
19. Wu, J.; Chen, W.; Xia, G.; Zhang, J.; Shao, J.; Tan, B.; Zhang, C.; Yu, W.; Weng, Q.; Liu, H.; Hu, M.; Deng, H.; Hao, Y.; Shen, J.; Yu, Y. Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR. ACS Med. Chem. Lett., 2013, 4, 974-978.
20. Sampson, P.B.; Liu, Y.; Patel, N.K.; Feher, M.; Forrest, B.; Li, S.W.; Edwards, L.; Laufer, R.; Lang, Y.; Ban, F.; Awrey, D.E.; Mao, G.; Plotnikova, O.; Leung, G.; Hodgson, R.; Mason, J.; Wei, X.; Kiarash, R.; Green, E.; Qiu, W.; Chirgadze, N.Y.; Mak, T.W.; Pan, G.; Pauls, H.W. The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro[cyclopropane-1,3′[3H]indol]-2′(1′H)-ones as Orally Bioavailable Antitumor Agents. J. Med. Chem., 2014 [Epub ahead of print].
21. Duan, Y.T.; Yao, Y.F.; Huang, W.; Makawana, J.A.; Teraiya, S.B.; Thumar, N.J.; Tang, D.J.; Tao, X.X.; Wang, Z.C.; Jiang, A.Q.; Zhu, H.L. Synthesis, biological evaluation, and molecular docking studies of novel 2-styryl-5-nitroimidazole derivatives containing 1,4-benzodioxan moiety as FAK inhibitors with anticancer activity. Bioorg. Med. Chem., 2014, 22, 2947-2954.
22. Dao, P.; Smith, N.; Tomkiewicz-Raulet, C.; Yen-Pon, E.; Camacho-Artacho, M.; Lietha, D.; Herbeuval, J.P.; Coumoul, X.; Garbay, C.; Chen, H. Design, Synthesis, and Evaluation of Novel Imidazo[1,2-a][1,3,5]triazines and Their Derivatives as Focal Adhesion Kinase Inhibitors with Antitumor Activity. J. Med. Chem., 2015, 58, 237-251.
23. Young, D.D.; Connelly, C.M.; Grohmann, C.; Deiters, A. Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J. Am. Chem. Soc., 2010, 132, 7976-7981.
24. Xiao, Z.; Li, C.H.; Chan, S.L.; Xu, F.; Feng, L.; Wang, Y.; Jiang, J.D.; Sung, J.J.; Cheng, C.H.; Chen, Y. A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma. Cancer Res., 2014, 74, 6236-6247.
25. Lopez-Lazaro, M. (2014) Experimental Cancer Pharmacology for Researchers: At What Concentration Should my Drug Kill Cancer Cells so that it has Potential for Cancer Therapy? Amazon Digital Services, Inc
26. Cheng, W.H.; Cao, B.; Shang, H.; Niu, C.; Zhang, L.M.; Zhang, Z.H.; Tian, D.L.; Zhang, S.; Chen, H.; Zou, Z.M. Synthesis and evaluation of novel podophyllotoxin derivatives as potential antitumor agents. Eur. J. Med. Chem., 2014, 85, 498-507.
27. Kim, J.H.; Yu, J.; Alexander, V.; Choi, J.H.; Song, J.; Lee, H.W.; Kim, H.O.; Choi, J.; Lee, S.K.; Jeong, L.S. Structure-activity relationships of 2′-modified-4′-selenoarabinofuranosyl-pyrimidines as anticancer agents. Eur. J. Med. Chem., 2014, 83, 208-225.
28. Alanazi, A.M.; Abdel-Aziz, A.A.; Al Suwaidan, I.A.; Abdel-Hamide, S.G.; Shawer, T.Z.; El Azab, A.S. Design, synthesis and biological evaluation of some novel substituted quinazolines as antitumor agents. Eur. J. Med. Chem., 2014, 79, 446-454.
29. Rodrigues, F.A.; Bomfim, I.S.; Cavalcanti, B.C.; Pessoa, C.O.; Wardell, J.L.; Wardell, S.M.; Pinheiro, A.C.; Kaiser, C.R.; Nogueira, T.C.; Low, J.N.; Gomes, L.R.; de Souza, M.V. Design, synthesis and biological evaluation of (E)-2-(2-arylhydrazinyl)quinoxalines, a promising and potent new class of anticancer agents. Bioorg. Med. Chem. Lett., 2014, 24, 934-939.
30. Liu, W.; Gust, R. Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. Chem. Soc. Rev., 2013, 42, 755-773.
31. Vega-Perez, J.M.; Perinan, I.; Argandona, M.; Vega-Holm, M.; Palo-Nieto, C.; Burgos-Moron, E.; Lopez-Lazaro, M.; Vargas, C.; Nieto, J.J.; Iglesias-Guerra, F. Isoprenyl-thiourea and urea derivatives as new farnesyl diphosphate analogues: synthesis and in vitro antimicrobial and cytotoxic activities. Eur. J. Med. Chem., 2012, 58, 591-612.
32. Vega-Perez, J.M.; Palo-Nieto, C.; Vega-Holm, M.; Gongora-Vargas, P.; Calderon-Montano, J.M.; Burgos-Moron, E.; Lopez-Lazaro, M.; Iglesias-Guerra, F. Aziridines from alkenyl-beta-D-galactopyranoside derivatives: Stereoselective synthesis and in vitro selective anticancer activity. Eur. J. Med. Chem., 2013, 70C, 380-392.
33. Lopez-Lazaro, M.; Willmore, E.; Jobson, A.; Gilroy, K.L.; Curtis, H.; Padget, K.; Austin, C.A. Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells. J Nat. Prod., 2007, 70, 1884-1888.
34. Burgos-Moron, E.; Calderon-Montano, J.M.; Salvador, J.; Robles, A.; Lopez-Lazaro, M. The dark side of curcumin. Int. J. Cancer, 2010, 126, 1771-1775.
35. Calderon-Montano, J.M.; Madrona, A.; Burgos-Moron, E.; Orta, M.L.; Mateos, S.; Espartero, J.L.; Lopez-Lazaro, M. Selective Cytotoxic Activity of New Lipophilic Hydroxytyrosol Alkyl Ether Derivatives. J. Agric. Food Chem., 2013, 61, 5046-5053.
36. Wang, Y.; Lonard, D.M.; Yu, Y.; Chow, D.C.; Palzkill, T.G.; Wang, J.; Qi, R.; Matzuk, A.J.; Song, X.; Madoux, F.; Hodder, P.; Chase, P.; Griffin, P.R.; Zhou, S.; Liao, L.; Xu, J.; O'Malley, B.W. Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res., 2014, 74, 1506-1517.
37. Clifford, R.J.; Kaplan, J.H. Human breast tumor cells are more resistant to cardiac glycoside toxicity than non-tumorigenic breast cells. PLoS. One., 2013, 8, e84306.
38. Calderon-Montano, J.M.; Burgos-Moron, E.; Orta, M.L.; Garcia-Dominguez, I.; Maldonado-Navas, D.; Lopez-Lazaro, M. Bufalin is a steroid receptor coactivator inhibitor-Letter. Cancer Res., 2015, doi: 10.1158/0008-5472.CAN-14-0398 (in press).
39. Calderon-Montano, J.M.; Burgos-Moron, E.; Lopez-Lazaro, M. The in vivo antitumor activity of cardiac glycosides in mice xenografted with human cancer cells is probably an experimental artifact. Oncogene, 2014, 33, 2947-2948.
40. Zhang, H.; Qian, D.Z.; Tan, Y.S.; Lee, K.; Gao, P.; Ren, Y.R.; Rey, S.; Hammers, H.; Chang, D.; Pili, R.; Dang, C.V.; Liu, J.O.; Semenza, G.L. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 19579-19586.
41. Hiyoshi, H.; Abdelhady, S.; Segerstrom, L.; Sveinbjornsson, B.; Nuriya, M.; Lundgren, T.K.; Desfrere, L.; Miyakawa, A.; Yasui, M.; Kogner, P.; Johnsen, J.I.; Andang, M.; Uhlen, P. Quiescence and gammaH2AX in neuroblastoma are regulated by ouabain/Na,K-ATPase. Br. J. Cancer, 2012, 106, 1807-1815.
42. Tailler, M.; Senovilla, L.; Lainey, E.; Thepot, S.; Metivier, D.; Sebert, M.; Baud, V.; Billot, K.; Fenaux, P.; Galluzzi, L.; Boehrer, S.; Kroemer, G.; Kepp, O. Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia. Oncogene, 2012, 31, 3536-3546.
43. Zhang, D.M.; Liu, J.S.; Deng, L.J.; Chen, M.F.; Yiu, A.; Cao, H.H.; Tian, H.Y.; Fung, K.P.; Kurihara, H.; Pan, J.X.; Ye, W.C. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. Carcinogenesis, 2013, 34, 1331-1342.
44. Lopez-Lazaro, M. Digoxin, HIF-1, and cancer. Proc. Natl. Acad. Sci. U. S. A., 2009, 106, E26.
45. Calderon-Montano, J.M.; Burgos-Moron, E.; Lopez-Lazaro, M. Comment on 'Quiescence and gammaH2AX in neuroblastoma are regulated by Ouabain/Na,K-ATPase': ouabain and cancer. Br. J. Cancer, 2013, 108, 2189-2190.
46. Kerbel, R.S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol. Ther., 2003, 2, S134-S139.
47. Hutchinson, L.; Kirk, R. High drug attrition rates - where are we going wrong? Nat. Rev. Clin. Oncol., 2011, 8, 189-190.
48. Begley, C.G.; Ellis, L.M. Drug development: Raise standards for preclinical cancer research. Nature, 2012, 483, 531-533.
49. Calderon-Montano, J.M.; Burgos-Moron, E.; Orta, M.L.; Maldonado-Navas, D.; Garcia-Dominguez, I.; Lopez-Lazaro, M. Evaluating the cancer therapeutic potential of cardiac glycosides. Biomed. Res. Int., 2014, 2014:794930.
50. Lopez-Lazaro, M. How many times should we screen a chemical library to discover an anticancer drug? 2014, Drug Discov. Today doi: 10.1016/j.drudis.2014.12.006. [Epub ahead of print]
51. Elhalem, E.; Recio, R.; Werner, S.; Lieder, F.; Calderon-Montano, J.M.; Lopez-Lazaro, M.; Fernandez, I.; Khiar, N. Sulforaphane homologues: Enantiodivergent synthesis of both enantiomers, activation of the Nrf2 transcription factor and selective cytotoxic activity. Eur. J. Med. Chem., 2014, 87C, 552-563.
52. Antonelli, A.; Bocci, G.; La Motta, C.; Ferrari, S.M.; Fallahi, P.; Fioravanti, A.; Sartini, S.; Minuto, M.; Piaggi, S.; Corti, A.; Ali, G.; Berti, P.; Fontanini, G.; Danesi, R.; Da Settimo, F.; Miccoli, P. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J. Clin. Endocrinol. Metab., 2011, 96, E288-E296.
53. Fallahi, P.; Ferrari, S.M.; Mazzi, V.; Vita, R.; Benvenga, S.; Antonelli, A. Personalization of targeted therapy in advanced thyroid cancer. Curr. Genomics., 2014, 15, 190-202.
54. Carrasco, E.; Alvarez, P.J.; Prados, J.; Melguizo, C.; Rama, A.R.; Aranega, A.; Rodriguez-Serrano, F. Cancer stem cells and their implication in breast cancer. Eur. J. Clin. Invest., 2014, 44, 678-687.
55. Dawood, S.; Austin, L.; Cristofanilli, M. Cancer Stem Cells: Implications for Cancer Therapy. Oncology (Williston. Park). 2014, 28, 202935.
56. Sandoval, M.; Harris, L. Cancer stem cells. Oncology (Williston. Park). 2014, 28, 202936.
57. Carrasco, E.; Alvarez, P.J.; Melguizo, C.; Prados, J.; Alvarez-Manzaneda, E.; Chahboun, R.; Messouri, I.; Vazquez-Vazquez, M.I.; Aranega, A.; Rodriguez-Serrano, F. Novel merosesquiterpene exerts a potent antitumor activity against breast cancer cells in vitro and in vivo. Eur. J. Med. Chem., 2014, 79, 1-12.
58. Riss, T.L.; Moravec, R.A.; Niles, A.L.; Benink, H.A.; Worzella, T.J.; Minor, L.; Riss, T.L.; Moravec, R.A.; Niles, A.L. Cell Viability Assays. Cytotoxicity testing: measuring viable cells, dead cells, and detecting mechanism of cell death. Methods Mol. Biol., 2011, 740, 103-114.
59. Niles, A.L.; Moravec, R.A.; Riss, T.L. In vitro viability and cytotoxicity testing and same-well multi-parametric combinations for high throughput screening. Curr. Chem. Genomics, 2009, 3, 33-41.
60. Niles, A.L.; Riss, T.L. Multiplexed viability, cytotoxicity, and caspase activity assays. Methods Mol. Biol., 2015, 1219, 21-33.
61. Hatzis, C.; Bedard, P.L.; Birkbak, N.J.; Beck, A.H.; Aerts, H.J.; Stem, D.F.; Shi, L.; Clarke, R.; Quackenbush, J.; Haibe-Kains, B. Enhancing reproducibility in cancer drug screening: how do we move forward? Cancer Res., 2014, 74, 4016-4023.
62. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; . Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 1991, 83, 757-766.
63. Vichai, V.; Kirtikara, K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc., 2006, 1, 1112-1116.
64. Sams-Dodd, F. Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug Discov. Today, 2013, 18, 211-217.
65. Strumberg, D.; Richly, H.; Hilger, R.A.; Schleucher, N.; Korfee, S.; Tewes, M.; Faghih, M.; Brendel, E.; Voliotis, D.; Haase, C.G.; Schwartz, B.; Awada, A.; Voigtmann, R.; Scheulen, M.E.; Seeber, S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol., 2005, 23, 965-972.
66. Cheng, A.L.; Kang, Y.K.; Chen, Z.; Tsao, C.J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.S.; Xu, J.; Sun, Y.; Liang, H.; Liu, J.; Wang, J.; Tak, W.Y.; Pan, H.; Burock, K.; Zou, J.; Voliotis, D.; Guan, Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol., 2009, 10, 25-34.
67. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T.F.; Galle, P.R.; Seitz, J.F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359, 378-390.